Mogrify Ltd has raised $16 million in an initial Series A round to support development of its direct cellular conversion technology. This represents a new approach to drug discovery by potentially enabling researchers to transform any mature human cell type into any other without going through a pluripotent stem cell state. Leading the round was Ahren Innovation Capital, an existing investor, with participation from Parkwalk, 24Haymarket and the University of Bristol Enterprise Fund III.
